IPH 2101: Phase IIa data

Innate said data from the open-label, French Phase IIa REMYKIR trial in about 28 patients with stable, measurable MM after induction therapy showed that maintenance therapy with IV IPH2101 as monotherapy given once every 4 weeks missed the primary endpoint of reducing M-protein levels. Details were not disclosed. ...